Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs)
An Open Label Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs) Who Developed Progressive Disease or Relapsed While on Imatinib Mesylate
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Age ≥ 18 years;
- Disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) during previous treatment with imatinib mesylate at least 600 mg daily for at least 8 weeks, as per two independently assessed prestudy computerized tomography (CT) scans;
- Presence of at least one measurable (per RECIST)
- Progressing tumor lesion not previously treated with radiotherapy or embolization and evaluable by CT scan or magnetic resonance imaging (MRI);
- Karnofsky performance status ≥ 60;
- imatinib treatment terminated at least 7 days before study day 1;
- Adequate hepatic, renal, and cardiac function.
Exclusion criteria:
- Prior malignancy (other than GIST, in situ cervical cancer, or basal cell cancer of the skin) unless treated with curative intent and without evidence of disease for ≥ 3 years; cardiac disease including myocardial infarction, unstable angina, and congestive heart failure (New York Heart Association class > II),
- uncontrolled hypertension (systolic > 145 mmHg or diastolic > 85 mmHg),
- History of arterial thrombosis or deep vein thrombosis (including pulmonary embolus) within 1 year of study day 1;
- Absolute neutrophil count < 1.5x109/L, platelet count < 100x109/L, hemoglobin < 9.0 g/dL;
- Prior treatment with motesanib diphosphate or other KIT (except imatinib) or VEGF inhibitors.
- The study was approved by the institutional review board of each participating institution, and all patients provided written informed consent before any study-related procedures were performed.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Arm
AMG 125 mg daily continuously
|
AMG 706 125 mg daily for 48 weeks, or until progressive disease or unacceptable toxicity.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Objective response rate as defined using modified RECIST criteria.
Time Frame: 48 weeks treatment or until progressive disease, or unacceptable toxicity
|
48 weeks treatment or until progressive disease, or unacceptable toxicity
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Progression-free survival
Time Frame: time from randomization to progressive disease
|
time from randomization to progressive disease
|
|
Overall survival
Time Frame: time to death
|
time to death
|
|
Time to progression
Time Frame: time from response to progressive disease
|
time from response to progressive disease
|
|
Time to response
Time Frame: time from first treatment to response
|
time from first treatment to response
|
|
Patient-reported outcomes
Time Frame: quality of life
|
quality of life
|
|
Use of opioid analgesics after minimal 6 months treatment
Time Frame: narcotics usage during study
|
narcotics usage during study
|
|
Objective response by PET and tumor size/density changes at week 8
Time Frame: response rate at week 8
|
response rate at week 8
|
|
Objective response by size changes and/or target tumor density changes at week 8
Time Frame: response rate at week 8
|
response rate at week 8
|
|
Safety Endpoints: Incidence of adverse events (including all, serious, grade 3, grade 4 and treatment related)
Time Frame: for duration of study
|
for duration of study
|
|
Duration of response
Time Frame: time to respone to progression
|
time to respone to progression
|
|
Palliative response
Time Frame: amelioration of symptoms
|
amelioration of symptoms
|
|
Pharmacokinetic Endpoints: 1. The AMG 706 PK parameters (Cmax, t1/2, AUC0-24, C24); 2. To explore the PK/PD relationships
Time Frame: during specific study timepoints
|
during specific study timepoints
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Neoplasms, Connective Tissue
- Gastrointestinal Stromal Tumors
- Gastrointestinal Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Protein Kinase Inhibitors
- Motesanib diphosphate
Other Study ID Numbers
Other Study ID Numbers
- 20040110
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.